37°

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
News
- Local News
- State News
Sports
- Local Sports
- Pro Sports
Lifestyle
- Local Entertainment
Multimedia
Community Choice
Features
Classifieds
- Place Ad
- Legal Notices
Public Notices
Obituaries
E-Edition

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

167.44 -0.54 (-0.32%)

Streaming Delayed Price Updated: 11:15 AM EST, Feb 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy. ↗

January 07, 2023

These stocks look cheap if you take a long-term view.

Via The Motley Fool

Will Investors Notice Exciting Sign On Jazz Pharmaceuticals's Chart? ↗

January 06, 2023

Via Benzinga

Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court ↗

January 05, 2023

Jazz Pharmaceuticals (NASDAQ: JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYS

Via Benzinga

2 Cannabis Stocks to Buy for the Long Haul ↗

December 31, 2022

Don't give up on this sector too quickly.

Via The Motley Fool

2 Growth Stocks to Buy Heading Into 2023 ↗

December 30, 2022

These biotechs are far from having achieved their full potential.

Via The Motley Fool

2 Top Biotech Stocks to Buy for the Long Haul ↗

December 25, 2022

These mid-cap biotechs are solid long-term choices.

Via The Motley Fool

Jazz Pharma Opts In, Advances Zanidatamab Partnership With Zymeworks ↗

December 21, 2022

Via Benzinga

6 Analysts Have This to Say About Jazz Pharmaceuticals ↗

December 09, 2022

Via Benzinga

What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals ↗

December 09, 2022

Via Benzinga

Is Axsome Therapeutics Stock a Buy Now? ↗

November 11, 2022

The company seems to be coming into its own.

Via The Motley Fool

Better Buy: Moderna vs Axsome ↗

December 22, 2022

Revenue prospects look promising for both of these biotech companies.

Via The Motley Fool

Tesla, Amazon, Micron, Sintx, Zymeworks: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

December 21, 2022

U.S. markets soared on Wednesday as consumer confidence surged to an eight-month high in December following a drop in inflation and the labor market remaining strong. Twelve-month inflation...

Via Benzinga

After Jumping 100%, Is Axsome a Buy Before 2023? ↗

December 16, 2022

Axsome's revenue story is just getting started.

Via The Motley Fool

Netflix To Rally Around 29%? Here Are 10 Other Price Target Changes For Friday ↗

December 09, 2022

Wells Fargo raised Netflix, Inc. (NASDAQ: NFLX) price target from $300 to $400. Wells Fargo also upgraded the stock from Equal Weight to Overweight. Netflix shares rose 0.6% to close at $310.26 on...

Via Benzinga

2 Unstoppable Growth Stocks to Buy in 2022 and Beyond ↗

December 08, 2022

These biotech players beat the bear market this year.

Via The Motley Fool

3 Fierce Stocks That Are Screaming Buys in December ↗

December 07, 2022

Here are three winners in the making.

Via The Motley Fool

Jazz Caregiver Survey: CBD-Based Epidiolex Improves Seizure & Non-Seizure Outcomes In Patients With Severe Epilepsy ↗

December 05, 2022

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) caregiver survey that showed a substantial proportion of caregivers...

Via Benzinga

Biotech Space Offers Reward In 2023 Despite Economic Risks ↗

November 30, 2022

Despite the economic headwinds, the mid-to long-term outlook for the biotech space remains strong, and investors who are able to take advantage of undervalued biotech stocks may be well-positioned for...

Via Talk Markets

Struggling Axsome Stock Could Bounce Back on Drug Trial Success

November 30, 2022

Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that.

Via MarketBeat

Q3 Proves To Be Another Tough Quarter For Cannabis ↗

November 28, 2022

It’s been a tough year for cannabis investors and Q3 offered little relief.

Via Talk Markets

Goldman Sachs, Walmart And These 2 Stocks Insiders Are Selling ↗

November 28, 2022

The Nasdaq Composite dropped around 0.5% on Friday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Want to Double Your Money? Buying These Stocks Could be a Genius Move ↗

November 28, 2022

These stocks are undervalued considering their long-term growth potential.

Via The Motley Fool

Prediction: This Growth Stock Could Double in 2023 ↗

November 24, 2022

The next year should be a busy one for this drugmaker.

Via The Motley Fool

Three CBD Stocks to Dominate a Budding Industry

November 23, 2022

The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity.

Via MarketBeat

Topics Cannabis

Analyst Bumps Up Price Target For Avadel Pharmaceuticals After Favorable Patent Ruling ↗

November 21, 2022

Last Friday, Delaware District Court granted Avadel Pharmaceuticals plc's (NASDAQ: AVDL) motion to delist the ‘963 Xyrem REMS patent.

Via Benzinga

Avadel Pharmaceuticals Announces Favorable Ruling Regarding Sleep Disorder Drug Patent ↗

November 21, 2022

Via Benzinga

Got $500? 3 Growth Stocks to Buy That Could Double Your Money ↗

November 20, 2022

Innovative products and services could keep these companies growing.

Via The Motley Fool

3 Top Cannabis Stocks to Buy in November ↗

November 20, 2022

These solid performers are managing to grow revenue in a difficult environment.

Via The Motley Fool

2 Dirt Cheap Growth Stocks to Buy and Hold for Years ↗

November 18, 2022

In the long run, these stocks could deliver great returns.

Via The Motley Fool

What 5 Analyst Ratings Have To Say About Jazz Pharmaceuticals ↗

November 10, 2022

Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings:

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Multimedia
Local Events
Classifieds
Obituaries
Weather
Online Features

Services

About Us
Contact Us
Promote Your Event
Subscriber Services
Online Forms
Rack Locations

woonsocketcall.com
Address: 154 Main Street
Woonsocket, RI 02895
Phone: 401-762-3000
Email: notices@woonsocketcall.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

All News about Jazz Pharmaceuticals plc - Ordinary Shares

Sections

Services